Brief: Innovation Pharma Says Covid-19 Drug Candidate Achieves Selectivity Index Exhibiting Potent Anti-Sars-Cov-2 Activity
24/08/2020 13:20
Aug 24 (Reuters) - Innovation Pharmaceuticals Inc IPIX.PK :
* COVID-19 DRUG CANDIDATE BRILACIDIN ACHIEVES A SELECTIVITY
INDEX
AMONG THE HIGHEST REPORTED, EXHIBITING POTENT ANTI-SARS-COV-2
ACTIVITY AT LOW CONCENTRATIONS; CLINICAL TRIAL FORTHCOMING
Source text for Eikon: ID:nGNX8xP1v2
Further company coverage: IPIX.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Innovation Pharmaceuticals
See all newsBrief: Innovation Pharmaceuticals Announces New Milestone At Beamed On Track To File 510(K) Submission To FDA In Q2 2024
Brief: Innovation Pharmaceuticals Provides Update On US Patent Applications Covering Use Of Brilacidin In Inflammatory Bowel Diseases, Coronaviruses And Fungal Diseases
Brief: Innovation Pharma Reports Enrollment In Phase 2 Trial Of Brilacidin For COVID-19 Tops 70%
Brief: Innovation Pharma Surpasses 50% Enrollment In Phase 2 Clinical Trial Of Brilacidin For COVID-19
Brief: Innovation Pharma Completes Interim Safety Data Review